Differentiated Therapeutics (dx/tx), a San Diego, and Cambridge, MA-based biotech company focused on computationally predicting and optimizing targeted protein degraders (TPDs), closed a $5m Seed financing.
Curie.Bio financed the round.
The company intends to use the funds to accelerate the development of novel disease-modifying targeted protein degraders against high value precision oncology targets.
Founded in 2021 by CEO Bryce Allen, PhD, COO Diala Ezzeddine, PhD, and Professor Isaac Kohane, MD PhD, of Harvard Medical School (HMS), Differentiated Therapeutics aims to design and develop disease-modifying TPD therapies for patients with unmet medical need. The company has built Auto/dx, a platform integrating proprietary methodologies in molecular simulation of protein interaction dynamics, AI, and synthetic biology.
Bryce Allen has a demonstrated track record in developing innovative computational approaches to designing small molecule therapeutics, most recently as a founding member of Silicon Therapeutics, acquired by Roivant Sciences in 2021 for $450 million. At Silicon, he was a key architect of the physics-based platform, and led the computationally-driven design and optimization of a best-in-class STING agonist currently in the clinic.
Diala Ezzeddine is an entrepreneur with a successful track record, including as founding CBO at X-Chem Pharmaceuticals, the premier DEL company she helped build and sell, and as founding CEO of venture-backed X-Chem spinoff, Xios Therapeutics.
Isaac Kohane is Chair of the Department of Biomedical Informatics at Harvard Medical School, and a thought leader in computationally-enabled medicine.
FinSMEs
01/08/2022